 Zoe Arvanitakis
Concepts (292)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain | 35 | 2020 | 1474 | 5.130 |
Why?
| | Alzheimer Disease | 37 | 2020 | 1688 | 4.900 |
Why?
| | Cognition Disorders | 28 | 2020 | 1063 | 4.250 |
Why?
| | Dementia | 19 | 2019 | 482 | 4.210 |
Why?
| | Diabetes Mellitus, Type 2 | 9 | 2020 | 220 | 3.420 |
Why?
| | Brain Infarction | 6 | 2020 | 74 | 2.380 |
Why?
| | Aged, 80 and over | 55 | 2020 | 5016 | 2.140 |
Why?
| | Diabetes Mellitus | 6 | 2020 | 131 | 2.120 |
Why?
| | Cognition | 15 | 2020 | 1067 | 2.060 |
Why?
| | Insulin | 5 | 2020 | 105 | 2.020 |
Why?
| | Cerebral Infarction | 6 | 2017 | 158 | 1.950 |
Why?
| | Antibodies, Antiphospholipid | 3 | 2019 | 24 | 1.940 |
Why?
| | Neurofibrillary Tangles | 7 | 2018 | 170 | 1.900 |
Why?
| | Aging | 22 | 2020 | 1484 | 1.840 |
Why?
| | Blood Pressure | 5 | 2020 | 248 | 1.790 |
Why?
| | tau Proteins | 8 | 2020 | 160 | 1.710 |
Why?
| | Neuropsychological Tests | 30 | 2019 | 1247 | 1.580 |
Why?
| | Humans | 84 | 2020 | 29841 | 1.490 |
Why?
| | Male | 67 | 2020 | 17153 | 1.410 |
Why?
| | Female | 68 | 2020 | 17657 | 1.400 |
Why?
| | Memory Disorders | 5 | 2020 | 173 | 1.380 |
Why?
| | Cerebrovascular Disorders | 3 | 2018 | 107 | 1.340 |
Why?
| | Aged | 52 | 2020 | 9833 | 1.330 |
Why?
| | Plaque, Amyloid | 6 | 2018 | 142 | 1.320 |
Why?
| | Amyloid beta-Peptides | 4 | 2020 | 221 | 1.210 |
Why?
| | Longitudinal Studies | 23 | 2020 | 1388 | 1.150 |
Why?
| | Cohort Studies | 20 | 2019 | 1911 | 1.120 |
Why?
| | European Continental Ancestry Group | 7 | 2020 | 593 | 1.060 |
Why?
| | Risk Factors | 20 | 2020 | 2549 | 1.050 |
Why?
| | Neuroimaging | 3 | 2019 | 108 | 1.010 |
Why?
| | African Continental Ancestry Group | 3 | 2018 | 172 | 0.980 |
Why?
| | White Matter | 4 | 2019 | 118 | 0.910 |
Why?
| | Hypoglycemic Agents | 3 | 2019 | 74 | 0.870 |
Why?
| | Body Mass Index | 3 | 2020 | 435 | 0.870 |
Why?
| | Adipokines | 1 | 2019 | 6 | 0.850 |
Why?
| | Signal Transduction | 3 | 2020 | 563 | 0.850 |
Why?
| | Drug Repositioning | 1 | 2019 | 4 | 0.850 |
Why?
| | Hypertension | 2 | 2020 | 266 | 0.830 |
Why?
| | Cerebral Arteries | 3 | 2016 | 37 | 0.830 |
Why?
| | Insulin-Like Growth Factor Binding Protein 5 | 1 | 2019 | 27 | 0.800 |
Why?
| | Parkinsonian Disorders | 5 | 2010 | 182 | 0.780 |
Why?
| | Cerebral Amyloid Angiopathy | 4 | 2016 | 82 | 0.770 |
Why?
| | Gray Matter | 2 | 2015 | 46 | 0.740 |
Why?
| | Geriatric Assessment | 3 | 2016 | 229 | 0.720 |
Why?
| | Diabetes Complications | 5 | 2016 | 66 | 0.720 |
Why?
| | Depressive Disorder | 1 | 2019 | 213 | 0.710 |
Why?
| | Follow-Up Studies | 9 | 2020 | 2017 | 0.630 |
Why?
| | Autopsy | 7 | 2020 | 292 | 0.620 |
Why?
| | Heme Oxygenase-1 | 3 | 2014 | 7 | 0.570 |
Why?
| | Epidemiologic Research Design | 1 | 2012 | 16 | 0.530 |
Why?
| | Hypercholesterolemia | 2 | 2010 | 37 | 0.520 |
Why?
| | Cross-Sectional Studies | 6 | 2020 | 915 | 0.510 |
Why?
| | Movement Disorders | 1 | 2012 | 134 | 0.470 |
Why?
| | Mental Status Schedule | 5 | 2018 | 121 | 0.470 |
Why?
| | Cardiovascular Diseases | 3 | 2020 | 370 | 0.450 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 72 | 0.450 |
Why?
| | Heptanoic Acids | 1 | 2010 | 5 | 0.440 |
Why?
| | Frontotemporal Dementia | 1 | 2010 | 9 | 0.440 |
Why?
| | Pyrroles | 1 | 2010 | 26 | 0.440 |
Why?
| | Neurodegenerative Diseases | 2 | 2001 | 103 | 0.430 |
Why?
| | Memory | 5 | 2020 | 332 | 0.410 |
Why?
| | Prospective Studies | 7 | 2020 | 1809 | 0.400 |
Why?
| | Age Factors | 4 | 2020 | 912 | 0.370 |
Why?
| | Apolipoprotein E4 | 5 | 2018 | 194 | 0.370 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 106 | 0.360 |
Why?
| | Asparagine | 1 | 2006 | 3 | 0.360 |
Why?
| | Lysine | 1 | 2006 | 14 | 0.360 |
Why?
| | Smoking | 3 | 2020 | 195 | 0.350 |
Why?
| | Linear Models | 3 | 2020 | 277 | 0.350 |
Why?
| | Independent Living | 2 | 2018 | 185 | 0.330 |
Why?
| | Gait Disorders, Neurologic | 2 | 2007 | 142 | 0.330 |
Why?
| | Logistic Models | 5 | 2017 | 478 | 0.330 |
Why?
| | Neuroglia | 2 | 2007 | 45 | 0.330 |
Why?
| | Incidence | 5 | 2020 | 813 | 0.320 |
Why?
| | Intracranial Arteriosclerosis | 2 | 2016 | 43 | 0.310 |
Why?
| | Postmortem Changes | 3 | 2019 | 35 | 0.310 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2005 | 40 | 0.310 |
Why?
| | Insulin Resistance | 2 | 2018 | 64 | 0.310 |
Why?
| | Lewy Body Disease | 4 | 2012 | 99 | 0.300 |
Why?
| | Diabetic Neuropathies | 1 | 2004 | 14 | 0.300 |
Why?
| | Hospitalization | 2 | 2018 | 330 | 0.300 |
Why?
| | Magnetic Resonance Imaging | 6 | 2015 | 1220 | 0.290 |
Why?
| | Mutation | 1 | 2006 | 445 | 0.290 |
Why?
| | Middle Aged | 17 | 2020 | 11053 | 0.290 |
Why?
| | African Americans | 5 | 2020 | 739 | 0.290 |
Why?
| | Insulin Receptor Substrate Proteins | 2 | 2014 | 14 | 0.280 |
Why?
| | Creatinine | 1 | 2002 | 56 | 0.260 |
Why?
| | Neuromuscular Diseases | 1 | 2001 | 12 | 0.240 |
Why?
| | Genetic Variation | 2 | 2016 | 117 | 0.220 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2019 | 21 | 0.210 |
Why?
| | Cholinesterase Inhibitors | 1 | 2019 | 20 | 0.210 |
Why?
| | Memantine | 1 | 2019 | 11 | 0.210 |
Why?
| | Arteriolosclerosis | 2 | 2018 | 39 | 0.210 |
Why?
| | Leptin | 1 | 2019 | 25 | 0.210 |
Why?
| | Cerebrovascular Circulation | 2 | 2019 | 56 | 0.210 |
Why?
| | Blood Pressure Determination | 1 | 2019 | 18 | 0.210 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2019 | 19 | 0.200 |
Why?
| | Frontal Lobe | 1 | 1999 | 87 | 0.200 |
Why?
| | Proteomics | 1 | 2019 | 58 | 0.200 |
Why?
| | Mycobacterium tuberculosis | 1 | 1998 | 18 | 0.200 |
Why?
| | Central Nervous System Infections | 1 | 1998 | 8 | 0.200 |
Why?
| | Vascular Diseases | 1 | 2019 | 53 | 0.190 |
Why?
| | Community Health Planning | 1 | 2018 | 21 | 0.190 |
Why?
| | Blood Glucose | 1 | 2019 | 133 | 0.190 |
Why?
| | Economics | 1 | 2018 | 23 | 0.190 |
Why?
| | Tuberculosis | 1 | 1998 | 24 | 0.190 |
Why?
| | Comorbidity | 4 | 2014 | 555 | 0.190 |
Why?
| | Brain Diseases | 1 | 1999 | 82 | 0.190 |
Why?
| | Temporal Lobe | 1 | 1999 | 112 | 0.190 |
Why?
| | Prefrontal Cortex | 1 | 2019 | 138 | 0.180 |
Why?
| | Sex Characteristics | 1 | 2018 | 123 | 0.180 |
Why?
| | Lewy Bodies | 3 | 2015 | 171 | 0.180 |
Why?
| | Health Literacy | 1 | 2018 | 91 | 0.170 |
Why?
| | Ambulatory Care | 1 | 2017 | 86 | 0.170 |
Why?
| | PubMed | 1 | 2016 | 12 | 0.170 |
Why?
| | Religious Personnel | 1 | 2016 | 11 | 0.170 |
Why?
| | Arterioles | 1 | 2016 | 16 | 0.170 |
Why?
| | Animals | 4 | 2016 | 5125 | 0.170 |
Why?
| | Organ Specificity | 1 | 2016 | 57 | 0.170 |
Why?
| | Nerve Degeneration | 2 | 2014 | 56 | 0.160 |
Why?
| | Chromosomes, Human, Pair 17 | 2 | 2006 | 12 | 0.160 |
Why?
| | Depression | 1 | 2020 | 490 | 0.150 |
Why?
| | beta 2-Glycoprotein I | 1 | 2014 | 7 | 0.150 |
Why?
| | Phosphatidylserines | 1 | 2014 | 7 | 0.150 |
Why?
| | Lupus Coagulation Inhibitor | 1 | 2014 | 7 | 0.150 |
Why?
| | Microglia | 1 | 2016 | 119 | 0.150 |
Why?
| | Serine | 1 | 2014 | 14 | 0.150 |
Why?
| | Autoantigens | 1 | 2014 | 36 | 0.150 |
Why?
| | Chronic Disease | 1 | 2017 | 530 | 0.150 |
Why?
| | Motor Skills | 1 | 2015 | 55 | 0.150 |
Why?
| | Tauopathies | 1 | 2014 | 15 | 0.150 |
Why?
| | Single-Blind Method | 1 | 2014 | 132 | 0.150 |
Why?
| | Diagnosis, Differential | 2 | 2010 | 466 | 0.150 |
Why?
| | Residence Characteristics | 1 | 2016 | 211 | 0.150 |
Why?
| | Inclusion Bodies | 1 | 2014 | 14 | 0.150 |
Why?
| | Risk Assessment | 3 | 2006 | 794 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 357 | 0.140 |
Why?
| | Neoplasms | 1 | 2017 | 264 | 0.140 |
Why?
| | Inflammation | 1 | 2016 | 338 | 0.140 |
Why?
| | Atrophy | 3 | 2005 | 99 | 0.130 |
Why?
| | Cerebral Cortex | 2 | 2006 | 195 | 0.130 |
Why?
| | Astrocytes | 1 | 2014 | 127 | 0.130 |
Why?
| | Membrane Proteins | 1 | 2014 | 205 | 0.130 |
Why?
| | Supranuclear Palsy, Progressive | 2 | 2003 | 43 | 0.130 |
Why?
| | Memory, Episodic | 1 | 2013 | 101 | 0.120 |
Why?
| | Hallucinations | 1 | 2012 | 94 | 0.120 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2012 | 60 | 0.120 |
Why?
| | Statistics as Topic | 3 | 2007 | 123 | 0.120 |
Why?
| | Motor Activity | 1 | 2015 | 387 | 0.120 |
Why?
| | Microcirculation | 1 | 2011 | 39 | 0.120 |
Why?
| | Amyloid | 1 | 2010 | 42 | 0.110 |
Why?
| | Chicago | 3 | 2020 | 916 | 0.110 |
Why?
| | Disease Progression | 3 | 2016 | 843 | 0.110 |
Why?
| | United States | 6 | 2020 | 2402 | 0.110 |
Why?
| | Clergy | 3 | 2006 | 81 | 0.110 |
Why?
| | Research Design | 1 | 2012 | 227 | 0.110 |
Why?
| | Dementia, Vascular | 2 | 2007 | 42 | 0.110 |
Why?
| | Terminology as Topic | 1 | 2010 | 52 | 0.110 |
Why?
| | Sterols | 1 | 2009 | 6 | 0.110 |
Why?
| | Family Health | 2 | 2006 | 40 | 0.110 |
Why?
| | Severity of Illness Index | 2 | 2015 | 1220 | 0.100 |
Why?
| | Public Health | 1 | 2010 | 62 | 0.100 |
Why?
| | Postural Balance | 2 | 2007 | 118 | 0.100 |
Why?
| | Glial Fibrillary Acidic Protein | 2 | 2007 | 37 | 0.100 |
Why?
| | Adult | 5 | 2020 | 9591 | 0.100 |
Why?
| | Accidental Falls | 1 | 2010 | 107 | 0.100 |
Why?
| | Intracranial Hemorrhages | 1 | 2008 | 18 | 0.090 |
Why?
| | Housing for the Elderly | 1 | 2007 | 8 | 0.090 |
Why?
| | Isometric Contraction | 1 | 2007 | 16 | 0.090 |
Why?
| | Receptors, Erythropoietin | 1 | 2007 | 2 | 0.090 |
Why?
| | Neuroprotective Agents | 1 | 2008 | 66 | 0.090 |
Why?
| | Lower Extremity | 1 | 2007 | 39 | 0.090 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2006 | 29 | 0.090 |
Why?
| | Decision Support Techniques | 1 | 2006 | 54 | 0.080 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 91 | 0.080 |
Why?
| | Leg | 1 | 2006 | 50 | 0.080 |
Why?
| | Gait | 2 | 2007 | 378 | 0.080 |
Why?
| | Muscle Strength | 1 | 2007 | 133 | 0.080 |
Why?
| | Visual Acuity | 1 | 2006 | 47 | 0.080 |
Why?
| | Spatial Behavior | 1 | 2006 | 22 | 0.080 |
Why?
| | Causality | 2 | 2020 | 58 | 0.080 |
Why?
| | Parkinson Disease | 3 | 2005 | 1112 | 0.080 |
Why?
| | Cell Count | 1 | 2005 | 115 | 0.080 |
Why?
| | alpha-Synuclein | 2 | 2018 | 137 | 0.080 |
Why?
| | Hypokinesia | 1 | 2004 | 25 | 0.080 |
Why?
| | DNA-Binding Proteins | 2 | 2018 | 245 | 0.080 |
Why?
| | Muscle Rigidity | 1 | 2004 | 27 | 0.080 |
Why?
| | Alleles | 2 | 2015 | 219 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2005 | 497 | 0.070 |
Why?
| | Heart Failure | 1 | 2007 | 222 | 0.070 |
Why?
| | Point Mutation | 1 | 2003 | 38 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2006 | 469 | 0.070 |
Why?
| | Tremor | 1 | 2004 | 107 | 0.070 |
Why?
| | Mice, Transgenic | 2 | 2014 | 293 | 0.070 |
Why?
| | Phosphorylation | 2 | 2014 | 189 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2002 | 29 | 0.060 |
Why?
| | Odds Ratio | 2 | 2017 | 328 | 0.060 |
Why?
| | Peptide Fragments | 1 | 2002 | 119 | 0.060 |
Why?
| | Socioeconomic Factors | 2 | 2018 | 351 | 0.060 |
Why?
| | Reference Values | 1 | 2002 | 255 | 0.060 |
Why?
| | Tomography, Emission-Computed | 1 | 2001 | 13 | 0.060 |
Why?
| | Aphasia, Primary Progressive | 1 | 2001 | 2 | 0.060 |
Why?
| | Spinocerebellar Degenerations | 1 | 2001 | 4 | 0.060 |
Why?
| | Heterozygote | 2 | 2015 | 101 | 0.060 |
Why?
| | Fatal Outcome | 1 | 2001 | 76 | 0.060 |
Why?
| | Apolipoproteins E | 2 | 2017 | 188 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 75 | 0.060 |
Why?
| | Stroke | 1 | 2004 | 340 | 0.060 |
Why?
| | Hippocampus | 2 | 2014 | 283 | 0.060 |
Why?
| | Genotype | 2 | 2015 | 435 | 0.050 |
Why?
| | AIDS Dementia Complex | 1 | 2000 | 38 | 0.050 |
Why?
| | National Institute on Aging (U.S.) | 1 | 2019 | 16 | 0.050 |
Why?
| | Life Style | 1 | 2020 | 199 | 0.050 |
Why?
| | Mice | 2 | 2014 | 1805 | 0.050 |
Why?
| | American Native Continental Ancestry Group | 1 | 1998 | 1 | 0.050 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1998 | 10 | 0.050 |
Why?
| | DNA Fingerprinting | 1 | 1998 | 6 | 0.050 |
Why?
| | Self Report | 1 | 2020 | 217 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2019 | 44 | 0.050 |
Why?
| | Meningitis | 1 | 1998 | 10 | 0.050 |
Why?
| | Antitubercular Agents | 1 | 1998 | 17 | 0.050 |
Why?
| | Canada | 1 | 1998 | 55 | 0.050 |
Why?
| | Species Specificity | 1 | 1998 | 77 | 0.050 |
Why?
| | Chi-Square Distribution | 1 | 2018 | 181 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2014 | 369 | 0.050 |
Why?
| | Likelihood Functions | 1 | 2017 | 31 | 0.040 |
Why?
| | Brazil | 1 | 2017 | 22 | 0.040 |
Why?
| | Exercise | 1 | 2020 | 397 | 0.040 |
Why?
| | Prognosis | 1 | 2020 | 1025 | 0.040 |
Why?
| | Regression Analysis | 2 | 2007 | 318 | 0.040 |
Why?
| | Arterial Pressure | 1 | 2016 | 11 | 0.040 |
Why?
| | Neurologic Examination | 2 | 2007 | 159 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2001 | 869 | 0.040 |
Why?
| | Diagnosis | 1 | 2015 | 24 | 0.040 |
Why?
| | Educational Status | 1 | 2017 | 271 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2017 | 390 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2016 | 124 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2015 | 43 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2015 | 87 | 0.040 |
Why?
| | Actigraphy | 1 | 2015 | 97 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2014 | 24 | 0.040 |
Why?
| | Green Fluorescent Proteins | 1 | 2014 | 41 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2014 | 77 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2015 | 386 | 0.040 |
Why?
| | Glycoproteins | 1 | 2014 | 66 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2013 | 44 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2015 | 684 | 0.030 |
Why?
| | Delusions | 1 | 2012 | 13 | 0.030 |
Why?
| | TDP-43 Proteinopathies | 1 | 2014 | 82 | 0.030 |
Why?
| | Epidemiologic Studies | 1 | 2012 | 23 | 0.030 |
Why?
| | Age of Onset | 1 | 2012 | 115 | 0.030 |
Why?
| | Phosphoserine | 1 | 2012 | 5 | 0.030 |
Why?
| | Cerebellar Cortex | 1 | 2012 | 9 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 529 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2012 | 43 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2013 | 231 | 0.030 |
Why?
| | Drug Resistance | 1 | 2012 | 67 | 0.030 |
Why?
| | Glucose | 1 | 2012 | 68 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2012 | 306 | 0.030 |
Why?
| | Rats | 1 | 2014 | 941 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2020 | 3788 | 0.030 |
Why?
| | Time Factors | 1 | 2016 | 1894 | 0.030 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 11 | 0.030 |
Why?
| | Neocortex | 1 | 2009 | 36 | 0.030 |
Why?
| | Models, Neurological | 1 | 2009 | 34 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 149 | 0.030 |
Why?
| | Cholesterol | 1 | 2009 | 65 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2009 | 142 | 0.030 |
Why?
| | Up-Regulation | 1 | 2009 | 214 | 0.020 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2007 | 37 | 0.020 |
Why?
| | Long-Term Care | 1 | 2007 | 57 | 0.020 |
Why?
| | Florida | 1 | 2006 | 17 | 0.020 |
Why?
| | Pedigree | 1 | 2006 | 86 | 0.020 |
Why?
| | Ambulatory Care Facilities | 1 | 2006 | 39 | 0.020 |
Why?
| | Community Health Services | 1 | 2006 | 31 | 0.020 |
Why?
| | Neurons | 1 | 2009 | 393 | 0.020 |
Why?
| | Brain Chemistry | 1 | 2005 | 51 | 0.020 |
Why?
| | Mobility Limitation | 1 | 2006 | 99 | 0.020 |
Why?
| | Syndrome | 1 | 2005 | 108 | 0.020 |
Why?
| | Observer Variation | 1 | 2005 | 140 | 0.020 |
Why?
| | Family | 1 | 2006 | 97 | 0.020 |
Why?
| | Antihypertensive Agents | 1 | 2005 | 85 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2007 | 327 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2007 | 345 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2006 | 617 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 592 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2005 | 379 | 0.020 |
Why?
| | Prevalence | 1 | 2006 | 533 | 0.020 |
Why?
| | Activities of Daily Living | 1 | 2007 | 470 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2006 | 382 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2006 | 857 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2005 | 3303 | 0.010 |
Why?
|
|
Arvanitakis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|